{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:39:38Z","timestamp":1790134778481,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":118,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001206.pub2","type":"reference-entry","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T07:10:33Z","timestamp":1097737833000},"source":"Crossref","is-referenced-by-count":35,"title":["Pharmacotherapy for social anxiety disorder"],"prefix":"10.1002","author":[{"given":"Dan J","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Ipser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton J","family":"van Balkom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,18]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1999.tb10845.x","article-title":"Paroxetine in social social anxiety disorder: a randomised placebo-controlled study","volume":"100","author":"Allgulander","year":"1999","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD001206.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1192\/bjp.175.2.120","article-title":"Paroxetine in social phobia \/social anxiety disorder. Randomised, double-blind, placebo-controlled study","volume":"175","author":"Baldwin","year":"1999","journal-title":"British Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","article-title":"Efficacy of olanzapine in social anxiety disorder: a pilot study","volume":"16","author":"Barnett","year":"2002","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.179.1.23","article-title":"Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia","volume":"179","author":"Blomhoff","year":"2001","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1176\/ajp.148.5.598","article-title":"The assessment and treatment of performance anxiety in musicians","volume":"148","author":"Clark","year":"1991","journal-title":"American Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004714-199810000-00004","article-title":"Discontinuation of clonazepam in the treatment of social phobia","volume":"18","author":"Connor","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004714-199312000-00008","article-title":"Treatment of social phobia with clonazepan and placebo","volume":"13","author":"Davidson","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB8|cit8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1600-0447.1995.tb09596.x","article-title":"Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study","volume":"92","author":"Fahlen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archpsyc.55.12.1133","article-title":"Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome","volume":"55","author":"Heimberg","year":"1998","journal-title":"Archives of General Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/014107688307600308","article-title":"Effect on pindolol on stress-related disturbances of musical performance: preliminary communication","volume":"76","author":"James","year":"1983","journal-title":"Journal of the Royal Society of Medicine"},{"key":"10.1002\/14651858.CD001206.pub2-BIB11|cit11","series-title":"Annual Meeting of the American Psychiatric Association, Philadelphia, PA","article-title":"Escitilopram is efficacious and well tolerated in the treatment of social anxiety disorder.","author":"Kasper","year":"2002"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB12|cit12","first-page":"71","article-title":"Moclobemide in social phobia. A double-blind, placebo-controlled clinical study","volume":"247","author":"Katschnig","year":"1997","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"9","key":"10.1002\/14651858.CD001206.pub2-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.152.9.1368","article-title":"Sertraline for social phobia: A double-blind, placebo-controlled crossover study","volume":"152","author":"Katzelnick","year":"1995","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200206000-00005","article-title":"Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study","volume":"22","author":"Kobak","year":"2002","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/archpsyc.49.4.290","article-title":"Phenelzine vs atenolol in social phobia: a placebo-controlled comparison","volume":"49","author":"Liebowitz","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","article-title":"Efficacy of sertraline in severe generalized social anxiety disorder: Results of a double-blind, placebo-controlled study","volume":"64","author":"Liebowitz","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004714-199708000-00003","article-title":"Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study","volume":"17","author":"Lott","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-199708000-00002","article-title":"Moclobemide in social phobia: A controlled dose response trial","volume":"17","author":"Noyes","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/cpp.291","article-title":"Cognitive therapy versus moclobemide in social phobia: A controlled study","volume":"8","author":"Oosterbaan","year":"2001","journal-title":"Clinical Pscyhology and Psychotherapy"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00004714-199908000-00010","article-title":"Treatment of social phobia with gabapentin: a placebo-controlled study","volume":"19","author":"Pande","year":"1999","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/da.1077","article-title":"Paroxetine for social anxiety and alcohol use in dual-diagnosed patients","volume":"14","author":"Randall","year":"2001","journal-title":"Depression & Anxiety"},{"key":"10.1002\/14651858.CD001206.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1192\/bjp.172.1.70","article-title":"Placebo-controlled trial of moclobemide in social phobia.","volume":"172","author":"Schneier","year":"1998","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00004714-199606000-00005","article-title":"Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation","volume":"16","author":"Stein","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","article-title":"Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial","volume":"280","author":"Stein","year":"1998","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","article-title":"Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study","volume":"156","author":"Stein","year":"1999","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00004850-200207000-00002","article-title":"Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder","volume":"17","author":"Stein","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archpsyc.59.12.1111","article-title":"Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study","volume":"59","author":"Stein","year":"2002","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S146114570300364X","article-title":"Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.","volume":"6","author":"Stein","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1037\/0022-006X.62.2.350","article-title":"Social phobia: A comparison of behaviour therapy and atenolol","volume":"62","author":"Turner","year":"1994","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","article-title":"Sertraline treatment of generalised social phobia: a 20-week, double-blind, placebo-controlled study","volume":"158","author":"Ameringen","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(92)90032-4","article-title":"Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor","volume":"2","author":"Vliet","year":"1992","journal-title":"European Neuropsychopharmacology"},{"issue":"1-2","key":"10.1002\/14651858.CD001206.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02244762","article-title":"Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine","volume":"115","author":"Vliet","year":"1994","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","article-title":"Clinical effects of busiprone in social phobia: a double-blind placebo-controlled study","volume":"58","author":"Vliet","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1192\/bjp.161.3.353","article-title":"Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine.","volume":"161","author":"Versiani","year":"1992","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB36|cit36","first-page":"167","article-title":"Double-blind placebo controlled trial with bromazepam in social phobia","volume":"46","author":"Versiani","year":"1997","journal-title":"Jornal Brasileiro de Psiquiatria"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/00004714-200012000-00009","article-title":"Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment","volume":"20","author":"Walker","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1185\/03007998409109561","article-title":"Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice","volume":"9","author":"Allsopp","year":"1984","journal-title":"Current Medical Research and Opinion"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hup.436","article-title":"Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings","volume":"2002","author":"Atmaca","year":"2002","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(82)90592-7","article-title":"Effects of beta-blockade and beta-stimulation on stage fright","volume":"72","author":"Brantigan","year":"1982","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1037\/0022-006X.71.6.1058","article-title":"Cognitive therapy versus fluoxetine in generalized social phobia: A randomized placebo-controlled trial","volume":"71","author":"Clark","year":"2003","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00005053-198103000-00005","article-title":"The treatment of social phobia: Real-life rehearsal with nonprofessional therapists","volume":"169","author":"Falloon","year":"1981","journal-title":"Journal of Nervous and Mental Disease"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD001206.pub2-BIB43|cit43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/000348948509400609","article-title":"Effect of beta-blockage on singing performance.","volume":"94","author":"Gates","year":"1985","journal-title":"Annals of Otology, Rhinology and Laryngology"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archpsyc.1991.01810340070009","article-title":"Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study","volume":"48","author":"Gelernter","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1192\/bjp.142.5.512","article-title":"The effect of beta adrenergic blockade on speaker's performance and memory","volume":"142","author":"Hartley","year":"1983","journal-title":"British Journal of Psychiatry"},{"issue":"8045","key":"10.1002\/14651858.CD001206.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(77)90890-X","article-title":"Effect of oxprenolol on stage-fright in musicians","volume":"2","author":"James","year":"1977","journal-title":"Lancet"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD001206.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-8703(84)90599-4","article-title":"Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo","volume":"108","author":"James","year":"1984","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD001206.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1185\/03007997609109311","article-title":"Oxprenolol in the treatment of examination stress","volume":"4","author":"Krishman","year":"1976","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD001206.pub2-BIB49|cit49","series-title":"9th European College of Neuropsychopharmacology, Amsterdam","article-title":"Pharmacological treatment of social phobia: A controlled study with alprazolam and buspirone","author":"Krylov","year":"1996"},{"issue":"1-3","key":"10.1002\/14651858.CD001206.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0165-0327(02)00094-0","article-title":"Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration","volume":"76","author":"Liappas","year":"2003","journal-title":"Journal of Affective Disorders"},{"issue":"7879","key":"10.1002\/14651858.CD001206.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(74)92060-1","article-title":"Beta-blocking agents in the treatment of catecholamine-induced symptoms in musicians","volume":"2","author":"Liden","year":"1974","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD001206.pub2-BIB52|cit52","first-page":"252","article-title":"Pharmacotherpy of social phobia: An interim report of placebo-controlled comparison of phenelzine and atenolol","volume":"49","author":"Liebowitz","year":"1988","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5","article-title":"Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome","volume":"10","author":"Liebowitz","year":"1999","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD001206.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1192\/bjp.131.5.486","article-title":"A clinical trial of phenelzine in anxiety depressive and phobic neuroses","volume":"131","author":"Mountjoy","year":"1977","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00006842-198211000-00008","article-title":"Stage fright in musicians: A model illustrating the effect of beta blockers","volume":"44","author":"Neftel","year":"1982","journal-title":"Psychosomatic Medicine"},{"key":"10.1002\/14651858.CD001206.pub2-BIB56|cit56","unstructured":"Oosterbaan D van Balkom A Spinhoven van Dyk R Cognitive behavior therapy versus moclobemide in social phobia WPA Thematic Conference, Jerusalem, Nov 1997"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0887-6185(00)00027-X","article-title":"A comparison of the efficacy of clonazepam and cognitive-behavioural group therapy for the treatment of social phobia","volume":"14","author":"Otto","year":"2000","journal-title":"Journal of Anxiety Disorders"},{"key":"10.1002\/14651858.CD001206.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1192\/bjp.140.5.484","article-title":"Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobicand social pobic patients","volume":"140","author":"Pecknold","year":"1982","journal-title":"British Journal of Psychiatry"},{"issue":"17","key":"10.1002\/14651858.CD001206.pub2-BIB59|cit59","first-page":"1279","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"34","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study","volume":"158","author":"Seedat","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB61|cit61","first-page":"393","article-title":"Effect of beta-blockade during bowling competition","volume":"8","author":"Siitonen","year":"1976","journal-title":"Annals of Clinical Research"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/070674377301800109","article-title":"Controlled evaluation of intravenous drugs in the specific desensitization of phobias","volume":"18","author":"Silverstone","year":"1973","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB63|cit63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/070674377301800106","article-title":"Behaviour therapy versus drug therapy in the treatment of phobic neurosis","volume":"18","author":"Solyom","year":"1973","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB64|cit64","first-page":"239","article-title":"Phenelzine and exposure in the treatment of phobias","volume":"16","author":"Solyom","year":"1981","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00422146","article-title":"A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety","volume":"32","author":"Tyrer","year":"1973","journal-title":"Psychopharmacologica"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","article-title":"Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine","volume":"19","author":"Allgulander","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","article-title":"Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.","volume":"177","author":"Stein","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub2-BIB68|cit68","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001206.pub2-BIB69|cit69","unstructured":"Ongoing study"},{"key":"10.1002\/14651858.CD001206.pub2-BIB70|cit70","unstructured":"Ongoing study"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB71|cit71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08039480310002110","article-title":"Phenelzine efficacy in refractory social anxiety disorder: a case series.","volume":"57","author":"Aarre","year":"2003","journal-title":"Nordic Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB72|cit72","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980"},{"issue":"8","key":"10.1002\/14651858.CD001206.pub2-BIB73|cit73","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM199708213370810","article-title":"The promise and problems of meta-analysis","volume":"337","author":"Bailar","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001206.pub2-BIB74|cit74","first-page":"54","article-title":"Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety","volume":"59 Suppl 17","author":"Ballenger","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB75|cit75","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15622970209150621","article-title":"WFSBP Task Force on Treatment Guidelines for Anxiety O-CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders","volume":"3","author":"Bandelow","year":"2002","journal-title":"World Journal of Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD001206.pub2-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.282.11.1083","article-title":"Measuring the quality of trials: The quality of quality scales","volume":"282","author":"Berlin","year":"1999","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB77|cit77","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0006-3223(01)01294-X","article-title":"Pharmacotherapy of social anxiety disorder","volume":"51","author":"Blanco","year":"2002","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB78|cit78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/da.10096","article-title":"Pharmalogical treatment of social anxiety disorder: A meta-analysis","volume":"18","author":"Blanco","year":"2003","journal-title":"Depression and Anxiety"},{"key":"10.1002\/14651858.CD001206.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0005-7967(79)90039-1","article-title":"Flooding with brevital in the treatment of agoraphobia - countereffective?","volume":"17","author":"Chambless","year":"1979","journal-title":"Behav Res Ther"},{"key":"10.1002\/14651858.CD001206.pub2-BIB80|cit80","first-page":"16","article-title":"Long-term treatment of social phobia with clonazepam","volume":"52 Suppl 1","author":"Davidson","year":"1991","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB81|cit81","first-page":"47","article-title":"Pharmacotherapy of social anxiety disorder.","volume":"59 Suppl 17","author":"Davidson","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB82|cit82","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD001206.pub2-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Statistics in medicine"},{"key":"10.1002\/14651858.CD001206.pub2-BIB84|cit84","article-title":"Cochrane Reviewers\u2019 Handbook 4.2.1 [updated December 2003]","volume-title":"The Cochrane Library","author":"Deeks","year":"2003"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB85|cit85","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","article-title":"Factors influencing the publication of research results: Follow-up of applications submitted to two substantial review boards","volume":"267","author":"Dickersin","year":"1992","journal-title":"JAMA"},{"issue":"8746","key":"10.1002\/14651858.CD001206.pub2-BIB86|cit86","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD001206.pub2-BIB87|cit87","first-page":"569","article-title":"Personality traits in social phobia, II: Changes during drug treatment","volume":"56","author":"Fahlen","year":"1995","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB88|cit88","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00004714-200106000-00011","article-title":"Psychological and pharmacological treatments of social phobia","volume":"21","author":"Fedoroff","year":"2001","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB89|cit89","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archpsyc.59.5.425","article-title":"Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy.","volume":"59","author":"Furmark","year":"2002","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-0327(87)90022-X","article-title":"Drug treatment of social phobia","volume":"13","author":"Gorman","year":"1987","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB91|cit91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1468-2850.1997.tb00123.x","article-title":"Cognitive-behavioral and pharmacological treatments of social phobia","volume":"4","author":"Gould","year":"1997","journal-title":"Clinical Psychology - Science & Practice"},{"key":"10.1002\/14651858.CD001206.pub2-BIB92|cit92","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD001206.pub2-BIB93|cit93","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"British Journal of Medical Psychology"},{"issue":"6","key":"10.1002\/14651858.CD001206.pub2-BIB94|cit94","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB95|cit95","first-page":"767","article-title":"Venalafaxine in social phobia.","volume":"31","author":"Kelsey","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB96|cit96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/archpsyc.1994.03950010008002","article-title":"Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United Sates: results from the National Comorbidity Survey","volume":"51","author":"Kessler","year":"1994","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB97|cit97","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11920-004-0076-y","article-title":"Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders","volume":"6","author":"Kuzma","year":"2004","journal-title":"Curr Psychiatry Rep."},{"issue":"7","key":"10.1002\/14651858.CD001206.pub2-BIB98|cit98","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archpsyc.1985.01790300097013","article-title":"Social phobia. Review of a neglected anxiety disorder.","volume":"42","author":"Liebowitz","year":"1985","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB99|cit99","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4088\/JCP.v63n0113","article-title":"A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder","volume":"63","author":"Liebowitz","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB100|cit100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0887-6185(03)00040-9","article-title":"How much do sample characteristics affect the effect size? An investigation of studies testing the treatment effects for social phobia.","volume":"18","author":"Lincoln","year":"2004","journal-title":"Journal of Anxiety Disorders"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB101|cit101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1176\/ajp.123.2.218","article-title":"Different ages of onset in varieties of phobias","volume":"123","author":"Marks","year":"1966","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD001206.pub2-BIB102|cit102","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1017\/S1461145701002474","article-title":"Taijin kyofusho: A form of social anxiety disorder that repsonds to serotonin reuptake inhibitors?","volume":"4","author":"Matsunaga","year":"2001","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"9193","key":"10.1002\/14651858.CD001206.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001206.pub2-BIB104|cit104","volume-title":"Cochrane Collaboration Handbook","author":"Mulrow","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB105|cit105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jama.1994.03520020084025","article-title":"Full publication of results initially presented in abstracts. A meta-analysis","volume":"272","author":"Scherer","year":"1994","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB106|cit106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/da.10112","article-title":"Citalopram treatment of social anxiety disorder with comorbid major depression","volume":"17","author":"Schneier","year":"2003","journal-title":"Depress and Anxiety"},{"key":"10.1002\/14651858.CD001206.pub2-BIB107|cit107","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11 Suppl 3","author":"Sheehan","year":"1996","journal-title":"International Clinical Psychopharmacology"},{"issue":"7387","key":"10.1002\/14651858.CD001206.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD001206.pub2-BIB109|cit109","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/jnp.10.1.96","article-title":"Is olfactory reference syndrome on the obsessive-compulsive spectrum? Two cases and a discussion","volume":"10","author":"Stein","year":"1998","journal-title":"Journal of Neuropsychiatry and Clinical Neuroscience"},{"issue":"10","key":"10.1002\/14651858.CD001206.pub2-BIB110|cit110","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Stein","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB111|cit111","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4088\/JCP.v63n0211","article-title":"Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials","volume":"63","author":"Stein","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001206.pub2-BIB112|cit112","series-title":"Presented at the ECNP Congress, Barcelona, Spain","article-title":"Paroxetine in social anxiety disorder: A remission analysis.","author":"Stein"},{"issue":"6965","key":"10.1002\/14651858.CD001206.pub2-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated.","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD001206.pub2-BIB114|cit114","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0005-7967(94)00086-Y","article-title":"Two-year follow-up of social phobias treated with Social Effectiveness Therapy.","volume":"33","author":"Turner","year":"1995","journal-title":"Behaviour Research and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD001206.pub2-BIB115|cit115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0165-0327(96)00030-4","article-title":"Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia","volume":"39","author":"Ameringen","year":"1996","journal-title":"Journal of Affective Disorders"},{"issue":"4","key":"10.1002\/14651858.CD001206.pub2-BIB116|cit116","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0193-953X(05)70263-X","article-title":"Pharmacotherapy of social anxiety disorder at the turn of the millennium.","volume":"24","author":"Ameringen","year":"2001","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1002\/14651858.CD001206.pub2-BIB117|cit117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-200008002-00004","article-title":"The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials","volume":"15 Suppl 2","author":"Linden","year":"2000","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001206.pub2-BIB118|cit118","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1192\/bjp.156.2.163","article-title":"Behavior therapy and benzodiazepines: allies or antagonists?","volume":"156","author":"Wardle","year":"1990","journal-title":"British Journal of Psychiatry"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001206.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001206.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T15:21:17Z","timestamp":1682781677000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001206.pub2"}},"subtitle":[],"editor":[{"given":"Dan J","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2004,10,18]]},"references-count":118,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001206.pub2","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD001206.pub3","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2004,10,18]]}}}